Tune Therapeutics

Tune Therapeutics is a biotechnology startup that aims to revolutionize genetic medicine through its innovative epigenomic control platform, TEMPO. Founded in 2020 and headquartered in the United States, the company's slogan, "Mastering the epigenome, unlocking complex disease," reflects its commitment to leveraging the epigenome to address a wide range of diseases. The company's $40.00M Series A investment in December 2021 garnered support from prominent investors including New Enterprise Associates, Emerson Collective, Hatteras Venture Partners, Mission BioCapital, and Saisei Ventures. Tune Therapeutics' pioneering approach of manipulating gene expression without altering DNA holds the potential to unlock treatment solutions for a myriad of complex and chronic diseases, including cancer, genetic disorders, and aging. This technology positions Tune Therapeutics at the forefront of a transformative shift in genetic medicine, expanding the scope of curative treatments beyond rare conditions to broader, more prevalent diseases.